CA2462682A1 - The use of gammaglobulin for the treatment of immune-mediated diseases - Google Patents

The use of gammaglobulin for the treatment of immune-mediated diseases Download PDF

Info

Publication number
CA2462682A1
CA2462682A1 CA002462682A CA2462682A CA2462682A1 CA 2462682 A1 CA2462682 A1 CA 2462682A1 CA 002462682 A CA002462682 A CA 002462682A CA 2462682 A CA2462682 A CA 2462682A CA 2462682 A1 CA2462682 A1 CA 2462682A1
Authority
CA
Canada
Prior art keywords
immunoglobulin
subject
immune
disease
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462682A
Other languages
English (en)
French (fr)
Inventor
Leon E. Barstow
Richard Weisbart
James A. Ostrem
F. Javier Enriquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462682A1 publication Critical patent/CA2462682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002462682A 2001-10-04 2002-10-04 The use of gammaglobulin for the treatment of immune-mediated diseases Abandoned CA2462682A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32704301P 2001-10-04 2001-10-04
US60/327,043 2001-10-04
US38096002P 2002-05-16 2002-05-16
US60/380,960 2002-05-16
PCT/US2002/033322 WO2003028668A2 (en) 2001-10-04 2002-10-04 Gammaglobulin treatment of immune disorders

Publications (1)

Publication Number Publication Date
CA2462682A1 true CA2462682A1 (en) 2003-04-10

Family

ID=26985697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462682A Abandoned CA2462682A1 (en) 2001-10-04 2002-10-04 The use of gammaglobulin for the treatment of immune-mediated diseases

Country Status (6)

Country Link
US (1) US20030099635A1 (https=)
EP (1) EP1463527A4 (https=)
JP (1) JP2005508338A (https=)
CA (1) CA2462682A1 (https=)
MX (1) MXPA04003156A (https=)
WO (1) WO2003028668A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222141A1 (en) * 2002-03-29 2003-10-13 Repligen Corporation Ctla4 compositions in the treatment of autism
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014911A2 (en) * 2004-07-26 2006-02-09 Kossor David C Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US20060205012A1 (en) 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2522754B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
EP2427497B1 (fr) * 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2560678A4 (en) * 2010-04-23 2013-09-18 Probiotec Ltd PHARMACEUTICAL COMPOSITIONS
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
SI2961426T1 (sl) 2013-02-26 2020-01-31 Baxalta GmbH Zdravljanje motenj centralnega živčnega sistema z intranazalnim dajanjem imunoglobulina G
HUE044737T2 (hu) 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
ES2690178A1 (es) * 2017-05-18 2018-11-19 Apc Europe Slu Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
DK0590060T3 (da) * 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
CA2290556A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
WO1999057152A1 (en) * 1998-05-07 1999-11-11 Research Corporation Technologies, Inc. Oral administration of immunoglobulins for treating autoimmune hearing loss
AU5583799A (en) * 1998-08-25 2000-03-14 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002542205A (ja) * 1999-04-19 2002-12-10 リチャード ワイスバート、 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders

Also Published As

Publication number Publication date
WO2003028668A3 (en) 2004-07-22
EP1463527A2 (en) 2004-10-06
EP1463527A4 (en) 2005-05-11
JP2005508338A (ja) 2005-03-31
MXPA04003156A (es) 2005-01-25
US20030099635A1 (en) 2003-05-29
WO2003028668A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US20030099635A1 (en) Use of oral gammaglobulin for the treatment of immune-mediated diseases
US10912955B2 (en) Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
US6187309B1 (en) Method for treatment of symptoms of central nervous system disorders
US20030099633A1 (en) Methods and compositions for treatment of immune dysfunction disorders
JP5781514B2 (ja) Ｈｓｐ６５由来のペプチド６に特異的なヒト化抗体、その方法及び使用
AU2003218206B2 (en) Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US20120045517A1 (en) TREATMENT OF CELIAC DISEASE WITH IgA
US8119104B2 (en) Treatment of celiac disease with IgA
AU2018213127A1 (en) Therapies for treating inflammatory disorders
US6200565B1 (en) Oral administration of immunoglobulins for treating autoimmune hearing loss
AU2002348464A1 (en) Gammaglobulin treatment of immune disorders
RU2342951C1 (ru) Препарат, содержащий иммуноглобулин противооспенный из сыворотки крови лошадей, раствор для внутримышечного введения
WO2006036213A2 (en) The use of gammaglobulin for the treatment of periodontal disease
US20250326821A1 (en) PROCESS FOR PREPARATION OF SECRETORY IgA AND SECRETORY IgM AND USE THEREOF FOR TREATING NECROTIZING ENTEROCOLITIS
US20200109185A1 (en) Treatment of intestinal dysbiosis with immunoglobin
Class et al. Patent application title: TREATMENT OF INTESTINAL DYSBIOSIS WITH IMMUNOGLOBIN
CA2370268A1 (en) Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
JP2026507912A (ja) 半合成ポリクローナルヒト分泌型免疫グロブリンａによる腸管腔免疫グロブリン欠乏の治療
JP2004525077A (ja) イムノグロブリンｇ強化血漿画分の経口投与による免疫媒介性疾病の治療

Legal Events

Date Code Title Description
FZDE Discontinued